MIPI: Summary for Molecular Insight Pharmaceutica - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Monday, November 23, 2009, 11:21am EST - Canadian Markets close in 4 hours and 39 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Molecular Insight Pharmaceuticals, Inc. (MIPI)

At 11:03 EST: 4.38 USD

0.15 (3.55%)

MORE ON MIPI

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Molecular Insight Pharmaceutica (NGM:MIPI) Delayed quote data

Last Trade:	4.38 USD
Trade Time:	11:03AM EST
Change:	0.15 (3.55%)
Prev Close:	4.23
Open:	4.33
Bid:	4.28 x 300
Ask:	4.40 x 300
1y Target Est:	19.00

Day's Range:	4.14 - 4.50
52wk Range:	1.15 - 7.90
Volume:	3,532
Avg Vol (3m):	41,150
Market Cap:	110.53M
P/E (ttm):	N/A
EPS (ttm):	-2.78
Div & Yield:	N/A (N/A%)

Molecular Insight Pharmaceuticals, Inc. (MIPI)

1d 5d 3m 6m 1y 2y 5y

Add MIPI to Portfolio

Download Data

HEADLINES

•	MOLECULAR INSIGHT PHARMACEUTICALS, INC. Financials
	EDGAR Online Financials (Fri, Nov 13)

•	Molecular Insight Pharmaceuticals to Present at Lazard Capital Markets Annual Healthcare Conference
	Marketwire (Wed, Nov 11)

•	Molecular Insight Pharmaceuticals, Inc Earnings Call scheduled for 4:30 pm ET today
	CCBN (Mon, Nov 9)

•	MOLECULAR INSIGHT PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Even
	EDGAR Online (Mon, Nov 9)

•	Molecular Insight Pharmaceuticals Reports Third Quarter 2009 Financial Results
	Marketwire (Mon, Nov 9)

•	Q3 2009 Molecular Insight Pharmaceuticals, Inc Earnings Release - Time Not Supplied
	CCBN (Mon, Nov 9)

•	MOLECULAR INSIGHT PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Mon, Nov 9)

•	Molecular Insight Pharmaceuticals, Inc. to Report Third Quarter Financial Results on November 9, 2009
	Marketwire (Mon, Oct 26)

•	Molecular Insight inks Onalta deals abroad
	at bizjournals.com (Fri, Oct 23)

•	Molecular Insight Pharmaceuticals Finalizes Onalta(TM) Manufacturing and Supply Agreements
	Marketwire (Wed, Oct 21)

More Headlines for MIPI...

ANALYST

EPS Est (next year) (Dec-07) :	N/A
EPS Est (in 2 years) (Dec-08) :	N/A
Avg Rec (current)*:	1.7
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Molecular Insight Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the research, development, and commercialization of molecular imaging pharmaceuticals and radiotherapeutics primarily in the areas of oncology and c...

Full Company Profile

Add to Portfolio

Email to a Friend

•